Semaglutide
US$ 21.52
compare glp 1 agonists Table from Glucagon-Like Peptide-1 (GLP-1) Receptor Drug Class Review Comparing GLP-type therapies for weight
Description
PMID 24571751
Jamil Alkhaddo, M.D., an endocrinologist based in California
The approved lanestype 2 diabetes and obesityblurred almost instantly
The global obesity GLP-1 market size accounted for USD 8.21 billion in 2025 and is predicted to increase from USD 10.12 billion in 2026 to approximately USD 66.57 billion by 2035, expanding at a CAGR of 23.28% from 2026 to 2035
This includes no influence on methodological frameworks, data interpretation, or final reporting of results
[DOI] [PubMed] [Google Scholar] 47.Munir K.M., Lamos E.M
